BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Several other drugs, including novel oxime derivatives of radicicol (71) and novobiocin (72), have been shown to be effective for the therapeutic intervention of CML by disrupting the Bcr–Abl–Hsp90 complex.